(株)ミズホメディーの貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証STD | 医薬品 | 4595/ - | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2020/10/09 | 日証協 | 709,734株 | -4.67% | 18,300株 | -82.65% | 611,771株 | -2.25% | 7,300株 | -89.5% |
2020/10/02 | 日証協 | 744,534株 | +4.58% | 105,460株 | -20.56% | 625,871株 | +2.65% | 69,500株 | -53.07% |
2020/09/25 | 日証協 | 711,926株 | +2.87% | 132,748株 | +190.63% | 609,690株 | +8.53% | 148,096株 | +161.94% |
2020/09/18 | 日証協 | 692,064株 | -5.51% | 45,676株 | -74.76% | 561,790株 | +1.35% | 56,538株 | -48.7% |
2020/09/11 | 日証協 | 732,402株 | +18.72% | 180,974株 | -58.88% | 554,328株 | +16.67% | 110,200株 | -28.3% |
2020/09/04 | 日証協 | 616,902株 | +47.9% | 440,106株 | +37.68% | 475,128株 | +37.27% | 153,700株 | +30.55% |
2020/08/28 | 日証協 | 417,102株 | +16.07% | 319,666株 | +34.26% | 346,128株 | +12.92% | 117,734株 | -3.58% |
2020/08/21 | 日証協 | 359,368株 | +69.09% | 238,086株 | +30.46% | 306,528株 | +27.3% | 122,105株 | +4.04% |
2020/08/14 | 日証協 | 212,534株 | +85.62% | 182,492株 | +487.06% | 240,794株 | +47.01% | 117,366株 | +2505.24% |
2020/08/07 | 日証協 | 114,500株 | +1.78% | 31,086株 | +357.15% | 163,794株 | +0.99% | 4,505株 | +165% |
2020/07/22 | 日証協 | 116,700株 | +19.45% | 39,600株 | -5.91% | 162,694株 | +5.72% | 12,800株 | +84.89% |
2020/07/17 | 日証協 | 97,700株 | -3.17% | 42,086株 | +72.16% | 153,894株 | -4.69% | 6,923株 | -31.46% |
2020/07/10 | 日証協 | 100,900株 | +6.21% | 24,446株 | -21.55% | 161,471株 | +4.87% | 10,100株 | -48.22% |
2020/07/03 | 日証協 | 95,000株 | +4.28% | 31,160株 | +549.17% | 153,971株 | +5.19% | 19,504株 | +105.31% |
2020/06/26 | 日証協 | 91,100株 | +3.52% | 4,800株 | -60.61% | 146,371株 | -3.43% | 9,500株 | -56.42% |
2020/06/12 | 日証協 | 110,300株 | -21.83% | 100株 | 0% | 170,971株 | +0.65% | 14,500株 | -67.78% |
2020/06/05 | 日証協 | 141,100株 | -24.99% | 100株 | -99.31% | 169,871株 | -11.97% | 45,000株 | +713.16% |
2020/05/29 | 日証協 | 188,100株 | -10.21% | 14,534株 | +2.35% | 192,971株 | -6.31% | 5,534株 | -66.06% |
2020/05/22 | 日証協 | 209,500株 | -5.6% | 14,200株 | -45.8% | 205,972株 | +1.43% | 16,303株 | -50.65% |
※株式分割は考慮していませんのでご注意ください。
Page Top